Phytonadione Works Best Where You'd Least Expect, and Fails Where It Seems Obvious
Phytonadione, the main dietary form of vitamin K, is one of those drugs that looks straightforward on paper but behaves unpredictably in practice. It reliably reverses warfarin-related bleeding, yet in chronic liver disease, where clotting is clearly impaired, it does essentially nothing. And in critically ill children with septic shock, it normalizes clotting in fewer than half. Where and how phytonadione is used matters enormously, and the assumptions people make about it don't always hold up. Phytonadione is FDA-approved for a specific set of conditions: reversing the effects of warfarin and other coumarin anticoagulants, treating hypoprothrombinemia caused by antibiotics, correcting vitamin K deficiency from malabsorption, and preventing or treating vitamin K-deficiency bleeding (VKDB) in newborns. Outside of those indications, the evidence gets thin fast.